Finished product reference

Erythrocytes (Red Blood Cell, Washed and Irradiated)

Injection · Parenteral · 270 mL

List code
52977
Pharmacologic class
Blood component (red blood cell concentrate)

What it is and how it works

Red cell concentrates are prepared from donated whole blood or by apheresis, with most plasma removed and usually suspended in an additive solution; they may be leucodepleted, irradiated or washed. Transfused red cells increase haemoglobin concentration and oxygen-carrying capacity.

Indications

Treatment of symptomatic anaemia and acute blood loss where oxygen delivery is inadequate, according to transfusion thresholds and clinical guidelines; exchange transfusion and chronic transfusion programmes (e.g. thalassaemia, sickle cell disease).

Dosage and administration (summary)

Dosing is individualised by the treating physician according to clinical condition, haemoglobin level and transfusion protocol; in adults one unit typically raises haemoglobin by about 10 g/L.

Contraindications

Not to be used when anaemia can be corrected by specific therapy (e.g. iron, vitamin B12, folate) without risk; transfusion must be ABO/RhD compatible and cross-matched.

Warnings and precautions

Serious risks include acute haemolytic reactions from ABO incompatibility, transfusion-associated circulatory overload, transfusion-related acute lung injury, allergic and febrile reactions, bacterial contamination and, rarely, transmission of infections. Strict patient identification and bedside checks are mandatory, and repeated transfusion can cause iron overload and alloimmunisation.

Pregnancy

May be transfused in pregnancy when indicated; RhD- and K-compatible, CMV-safe units are preferred.

Storage and supply

Store at 2–6 °C in a monitored blood refrigerator; transfuse within the time limits set by transfusion guidelines once removed from controlled storage.

Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.

Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.

Tell us the quantity, the market and the timing.

Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.

Telephone+98 21 8888 3325 · office hours 09:00–17:00, Tehran
OfficeHaniya Parsan Darou, 3rd floor, No. 326, Zafar Street, Africa Boulevard, Tehran 1968734974, Iran
Emailcontact@hanpars.com